Everett Harris & Co. CA Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Everett Harris & Co. CA lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 224,253 shares of the biopharmaceutical company’s stock after buying an additional 5,909 shares during the quarter. Everett Harris & Co. CA’s holdings in Pfizer were worth $5,949,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter worth about $31,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Pfizer by 60.3% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 583,600 shares of the biopharmaceutical company’s stock valued at $16,329,000 after acquiring an additional 219,600 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in Pfizer by 71.8% in the third quarter. Central Pacific Bank Trust Division now owns 9,286 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 3,880 shares in the last quarter. Czech National Bank grew its holdings in shares of Pfizer by 6.9% during the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after purchasing an additional 74,737 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. lifted its holdings in shares of Pfizer by 23.6% in the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 235,277 shares of the biopharmaceutical company’s stock valued at $6,809,000 after purchasing an additional 44,957 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.5 %

PFE stock opened at $26.51 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $150.20 billion, a P/E ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. The company has a 50 day moving average price of $26.25 and a two-hundred day moving average price of $27.89. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.49%. Pfizer’s dividend payout ratio is 232.44%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.